Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: UBS Upgrades RBS To Buy From Neutral

Tue, 21st Apr 2020 09:36

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

----------

FTSE 100

----------

LIBERUM RAISES CRODA INTERNATIONAL TO 'BUY' ('HOLD') - TARGET 5100 (4700) PENCE

----------

UBS RAISES RBS TO 'BUY' ('NEUTRAL') - PRICE TARGET 150 (215) PENCE

----------

GOLDMAN SACHS CUTS BHP GROUP PRICE TARGET TO 1680 (1700) PENCE - 'BUY'

----------

RBC CUTS LAND SECURITIES PRICE TARGET TO 825 (1100) PENCE - 'OUTPERFORM'

----------

RBC CUTS BRITISH LAND PRICE TARGET TO 455 (575) PENCE - 'SECTOR PERFORM'

----------

KEPLER CHEUVREUX RAISES ASTRAZENECA PRICE TARGET TO 8300 (7700) PENCE - 'BUY'

----------

JPMORGAN CUTS ST JAMES'S PLACE PRICE TARGET TO 937 (1325) PENCE - 'OVERWEIGHT'

----------

JPMORGAN CUTS PRUDENTIAL PRICE TARGET TO 1031 (1425) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS PHOENIX GROUP PRICE TARGET TO 786 (904) PENCE - 'OVERWEIGHT'

----------

JPMORGAN CUTS LEGAL & GENERAL PRICE TARGET TO 200 (284) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS AVIVA PRICE TARGET TO 332 (498) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS BP PRICE TARGET TO 425 (475) PENCE - 'OVERWEIGHT'

----------

JPMORGAN CUTS ROYAL DUTCH SHELL A PRICE TARGET TO 1650 (1750) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS SHELL B PRICE TARGET TO 1650 (1750) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS TAYLOR WIMPEY PRICE TARGET TO 186 (206) PENCE - 'BUY'

----------

JEFFERIES CUTS PERSIMMON PRICE TARGET TO 3245 (3531) PENCE - 'BUY'

----------

JEFFERIES CUTS BERKELEY GROUP PRICE TARGET TO 5727 (5779) PENCE - 'BUY'

----------

JEFFERIES CUTS BARRATT DEVELOPMENTS PRICE TARGET TO 659 (729) PENCE - 'BUY'

----------

GOLDMAN CUTS PEARSON PRICE TARGET TO 625.2 (658) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

GOLDMAN CUTS CAPITA TO 'BUY' ('CONVICTION BUY LIST') - TARGET 70 (200) PENCE

----------

BANK OF AMERICA INITIATES INVESTEC WITH 'BUY' - PRICE TARGET 190 PENCE

----------

LIBERUM CUTS BIG YELLOW GROUP PRICE TARGET TO 1000 (1100) PENCE - 'HOLD'

----------

RBC CUTS GREAT PORTLAND PRICE TARGET TO 550 (600) PENCE - 'UNDERPERFORM'

----------

RBC CUTS DERWENT LONDON PRICE TARGET TO 2750 (2900) PENCE - 'UNDERPERFORM'

----------

JPMORGAN CUTS JUST GROUP PRICE TARGET TO 59 (79) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS MITCHELLS & BUTLERS PRICE TARGET TO 400 (530) PENCE - 'BUY'

----------

JEFFERIES CUTS MARSTONS PRICE TARGET TO 35 (90) PENCE - 'UNDERPERFORM'

----------

JEFFERIES RAISES JD WETHERSPOON TO 'BUY' ('HOLD') - TARGET 1150 (1590) PENCE

----------

JEFFERIES CUTS REDROW PRICE TARGET TO 697 (809) PENCE - 'BUY'

----------

JEFFERIES CUTS CREST NICHOLSON PRICE TARGET TO 331 (362) PENCE - 'BUY'

----------

JEFFERIES CUTS COUNTRYSIDE PROPERTIES PRICE TARGET TO 587 (606) PENCE - 'BUY'

----------

JEFFERIES CUTS BELLWAY PRICE TARGET TO 3942 (4180) PENCE - 'BUY'

----------

OTHER MAIN MARKET AND AIM

----------

INVESTEC CUTS PREMIER OIL TO 'HOLD' ('BUY') - TARGET 25 (135) PENCE

----------

SHORE CAPITAL RESUMES HOLLYWOOD BOWL WITH 'BUY'

----------

LIBERUM RESUMES JOULES WITH 'BUY'

----------

JEFFERIES CUTS RESTAURANT GROUP PRICE TARGET TO 80 (170) PENCE - 'BUY'

----------

KEPLER CHEUVREUX CUTS HUNTING PRICE TARGET TO 230 (240) PENCE - 'HOLD'

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.